


## **Supplementary Figure 1**

Kaplan-Meier analyses based on cytokine values. Graphs (A-B) show Kaplan-Meier curves based on tertiles of IL-6 values derived from the current cohort of *BMPR2mut* (A) and PAH sans mutation (B) patients. Graphs (C-D) show Kaplan-Meier curves based on tertiles of TNF- $\alpha$  values derived from the current cohort of *BMPR2mut* (C) and PAH sans mutation (D) patients. Graphs (E-F) show Kaplan-Meier curves based on tertiles of IL-8 values derived from the current cohort of *BMPR2mut* (E) and PAH sans mutation (F) patients.




**Supplementary Figure 2**


Kaplan-Meier analyses based on NT-proBNP values. Graphs (A-B) show Kaplan-Meier curves

based on tertiles derived from the current cohort of *BMPR2mut* (A) and PAH sans mutation (B)

patients. Graphs (C-D) show Kaplan-Meier curves based on European Respiratory Society definitions of 'low' (<300ng/l) and 'high' (>1,400ng/l) values of NT-proBNP for *BMPR2mut* (C) and PAH sans mutation (D) patients.



Patients at risk	0yrs	1yr	2yrs	3yrs	4yrs
All PAH: IL-6< 1.6pg/ml	60	60	55	49	28
All PAH: IL-6> 1.6pg/ml	48	43	37	31	15



Patients at risk	0yrs	1yr	2yrs	3yrs	4yrs
PAH sans mutation: IL-6< 1.6pg/ml	32	32	29	27	14
PAH sans mutation: IL-6> 1.6pg/ml	22	22	18	15	09

### Supplementary Figure 3

Kaplan-Meier analyses based on a proposed cut-off value of 1.6pg/ml (median value for IL-6 in the *BMPR2mut* cohort and in the IPAH Simpson cohort). Graph (A) shows a Kaplan-Meier curve from the entire group of PAH patients and graph (B) shows the corresponding analysis in PAH without driving mutations alone.